Study Summary
This trial will study whether the LIPOSORBER® LA-15 System is an effective and safe treatment for patients with nephrotic syndrome associated with FSGS who have failed or not well tolerated standard treatments.
- Focal Segmental Glomerulosclerosis
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 1 Secondary · Reporting Duration: 1 month after the final Apheresis treatment.
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
1 Treatment Group
LIPOSORBER® LA-15 System
1 of 1
Experimental Treatment
35 Total Participants · 1 Treatment Group
Primary Treatment: LIPOSORBER® LA-15 · No Placebo Group · N/A
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age No minimum age - 75 · All Participants · 0 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
How many physical sites are conducting this investigation?
"This investigation is actively being conducted in 10 different sites, including Chapel Hill, Akron and Wilmington. To limit any necessary journeying for enrolment, participants should carefully select the trials nearest to them." - Anonymous Online Contributor
How many people have enrolled in this research project?
"Absolutely. Clinicaltrials.gov indicates that this research trial, which was first uploaded on January 1st 2020, is actively looking to enrol participants. 35 people are needed from 10 different sites." - Anonymous Online Contributor
Does this research have any age restrictions?
"In accordance with the eligibility criteria, children under 0 and adults up to 75 years old may participate in this clinical research." - Anonymous Online Contributor
Are there any openings in this clinical research study?
"That is accurate. According to the data on clinicaltrials.gov, this experiment was first advertised in January 2020 and has been actively seeking participants since then with a most recent update occurring at the end of March 2021. The trial requires 35 volunteers from 10 medical sites." - Anonymous Online Contributor
What prerequisites must be met in order to become a participant of this medical experiment?
"The trial seeks 35 hyalinosis, segmental glomerular patients aged between 0-75. To be eligible for the study, individuals must have either failed to respond or experienced adverse effects from corticosteroid and/or calcineurin inhibitors treatments with a GFR ≥45 ml/min/1.73 m2., or they should already had undergone renal transplantation." - Anonymous Online Contributor